Physician profile
Amy L Trace
NPI 1841308566
$3,333.08
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $974 · 2020: $310 · 2021: $474 · 2022: $175 · 2023: $907 · 2024: $494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,400.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $678.78 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $304.49 | 2019-2024 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $272.76 | 2019-2024 | |
| Esperion Therapeutics, INC. | $238.03 | 2020-2021 | |
| Amgen INC. | $215.86 | 2019-2022 | |
| Lilly USA, LLC | $195.54 | 2019-2024 | Mounjaro |
| Janssen Pharmaceuticals, INC | $163.81 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $159.57 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $152.01 | 2019-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Dexcom, INC. | $119.00 | 2023 | Dexcom G7 Gss (161) |
| Astellas Pharma US INC | $81.55 | 2019-2024 | Veozah |
| Glaxosmithkline, LLC. | $76.02 | 2022-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.41 | 2019-2024 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals Lp | $63.23 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $57.86 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $48.46 | 2019-2021 | |
| Antares Pharma, INC. | $41.03 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $36.80 | 2023 | Rexulti |
| Exact Sciences Corporation | $31.70 | 2023-2024 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $29.09 | 2023 | Quviviq |
| Abbott Laboratories | $27.89 | 2021-2024 | Freestyle Libre 3 |
| Currax Pharmaceuticals LLC | $27.55 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.34 | 2023 | Tradjenta, Jardiance |
| Genzyme Corporation | $24.46 | 2019-2020 | |
| Amarin Pharma, INC. | $24.09 | 2020-2021 | |
| Seqirus USA INC | $17.83 | 2020 | |
| Tris Pharma INC | $17.35 | 2024 | Dyanavel Xr |
| Ibsa Pharma INC. | $16.44 | 2023 | Tirosint, Licart |
| Corium, LLC | $15.85 | 2023 | Azstarys |
| Cranial Technologies, INC | $15.52 | 2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $15.19 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $14.79 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.41 | 2024 | Eliquis |
| Neos Therapeutics, Lp | $14.24 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.00 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Trace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.